Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London
(plain text version here)
Primary Cemiplimab treatment for orbital and periocular locally advanced Squamous Cell Carcinoma: A Case Series
Author: Nirodha Jayawickrema
ePoster Number: 205
Purpose
To evaluate the efficacy of Cemiplimab, a human monoclonal programmed cell death-1 (PD-1) receptor antibody as primary treatment of Periocular Locally Advanced Squamous Cell Carcinoma (PLA-SCC) to achieve tumour control, prevention of orbital exenteration (OE), & vision preservation.
Methods
Single centre, retrospective consecutive case review of patients (≥18 years) with biopsy proven PLA-SCC, treated with cemiplimab between January 2023 – January 2025 at Moorfields Eye Hospital NHS Trust, UK. Indications for treatment: locally advanced or metastatic disease not amenable to surgery/radiation, to avoid OE, unsuitable for surgery or patient choice. Intravenous cemiplimab 350 mg administered every three weeks. Discontinuation was considered due to disease progression, Adverse Effects (AE), patient preference, sustained complete response (CR), or clinical judgement.
Results
5 patients included, 3 (60%) females. Mean age at diagnosis 68 yrs (43–79). 4 (80%) had orbital invasion, 1 (25%) with intracranial spread into cavernous sinus & Meckel’s cave. 1 (20%) without orbital invasion. Perineural invasion in 2 (40%). None had metastases. Mean treatment duration, 10.9 months ( 2.1–14.9), mean of 14 doses (3–21). AE: 2 (40%) – hypothyroidism & continued treatment. 1 (20%) – grade 2 hepatitis & discontinued treatment. Outcome evaluation with Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, 1 (20%) – CR after 7.6 months of treatment, 1 (20%) had CR of lid lesion & partial response (PR) of intracranial lesion, 1 (20%) had PR, & 1 (20%) showed progression. For 1 (20%), RECIST criteria could not be applied due to small lesion size, but imaging showed CR after 7.5 months of treatment. Mean follow-up, 30.7 months (11.6–60.8). 1 (20%) underwent OE after tumour progression at 3 doses. Another had recurrence 12 months after stopping cemiplimab due to AE.3 patients had recorded visual acuities (VA) at conclusion: patient 1 – 6/6 & 2 – 6/5, patient 3 – HM due to pre-existing scarring. None got metastases.
Conclusion
Cemiplimab is effective for PLA-SCC with tumour control & eye preservation with an acceptable safety profile.
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Mumta | Kanda | Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom |
| Indran | Devagnanam | Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom |
| Claire | Daniel | Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom |
Abstract ID: 25-558